Healios K.K (TYO:4593) has launched a medical materials and equipment division to secure a steady supply of culture supernatant and expand its business, according to a Friday filing on the Tokyo Stock Exchange.
The division will manage production, quality control, and regulatory compliance, and support market research and customer engagement.
This follows Healios' partnership with AND medical group to supply culture supernatant for new treatments and cosmetics. Healios is also seeking conditional approval in Japan for its MultiStem therapy targeting acute respiratory distress syndrome (ARDS).
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。